secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0000950103-25-015818
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics reports 89.8% ORR and 77.6% CR in LOTIS-7 trial of ZYNLONTA + glofitamab in r/r DLBCL
--------------------------------------------------------------------------------

- Best ORR 89.8% (44/49); CR rate 77.6% (38/49) across dose levels.
- At 150 µg/kg dose, ORR 85.7% and CR 75.0%.
- In primary refractory patients (n=25): ORR 80%, CR 64%.
- Of 8 prior CAR-T patients, 6 achieved CR.
- Grade 3+ neutropenia (32.7%); manageable safety profile overall.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325015818/0000950103-25-015818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325015818/dp238449_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-015818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer